<DOC>
	<DOCNO>NCT01674062</DOCNO>
	<brief_summary>This study evaluate efficacy safety Perjeta ( pertuzumab ) combination Herceptin ( trastuzumab ) participant metastatic breast cancer progress trastuzumab-based therapy ( Cohorts 1 2 ) , make preliminary assessment efficacy safety single-agent pertuzumab ( Cohort 3 ) . Objective response rate clinical benefit assess . Pertuzumab administer initial dose 840 milligram ( mg ) intravenously ( IV ) Day 1 , follow 420 mg IV every 3 week . Trastuzumab administer schedule participant follow entry study . An additional cohort participant certain center receive pertuzumab monotherapy initial dose 840 mg IV Day 1 , follow 420 mg IV every 3 week . These participant may trastuzumab added regimen event progression single-agent pertuzumab treatment .</brief_summary>
	<brief_title>A Study Perjeta ( Pertuzumab ) Combination With Herceptin ( Trastuzumab ) Participants With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Females great equal ( ≥ ) 18 year age , histologicallyconfirmed HER2positive breast cancer Metastatic breast cancer , progression trastuzumabbased therapy last treatment metastatic disease Less equal ( ≤ ) 3 chemotherapy regimen prior study entry Last trastuzumab dose ≤9 week study entry participant receive pertuzumab + trastuzumab , ≥4 week participant receive pertuzumab monotherapy Left ventricular ejection fraction ≥55 % study entry Previous treatment anticancer vaccine target therapy trastuzumab Brain metastases History cardiac adverse event relate trastuzumab therapy Any malignancy last 5 year , except basal cell cancer cancer situ cervix</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>